Ipsen and Its Partner Exelixis Announce Positive Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma Presented at the European Soc
Go back to Ipsen and Its Partner Exelixis Announce Positive Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma Presented at the European Soc| Exelixis, Inc. (NASDAQ: EXEL) | Delayed: 51.34 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $51.34 | 52 Week High | $17.00 | |||
| Open | $51.34 | 52 Week Low | $3.55 | |||
| Day High | $51.34 | P/E | N/A | |||
| Day Low | $51.34 | EPS | $-1.33 | |||
| Volume | 426 | |||||
| SPDR S&P INTERNATIONAL INDUSTRIAL SECTOR (NYSE: IPN) | Delayed: 34.71 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $34.71 | 52 Week High | $30.88 | |||
| Open | $0.00 | 52 Week Low | $24.64 | |||
| Day High | $34.71 | P/E | N/A | |||
| Day Low | $34.71 | EPS | $0.00 | |||
| Volume | 741,680 | |||||
| Ipsen S.A. Sponsored ADR (AMEX: IPSEY) | Delayed: 46.50 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $46.50 | 52 Week High | $17.79 | |||
| Open | $46.50 | 52 Week Low | $13.01 | |||
| Day High | $46.50 | P/E | N/A | |||
| Day Low | $46.50 | EPS | $0.00 | |||
| Volume | 11 | |||||
